The 7th Annual International Conference „Good Distribution Practise, Cooperation and Partnership“…
Menu
Menu
The 7th Annual International Conference „Good Distribution Practise, Cooperation and Partnership“…
Rhei Life is pleased to announce that as of April 1st 2022, Olivera Kravic has joined our team
In 2021, Rhei Life demonstrated great strength in a challenging market environment, generating growth across all divisions.
Two products from our CHC portflio will be launched in H2 2022. in Myanmar due to signed partnership with company Healthy Max from Myanmar.
Along with our partners, we have extended the contract for BCG vaccine supply with the Croatian Institute for Public Health for an additional 3 years, above the 3 years already in collaboration.
A new agreement has been signed and a new partnership confirmed with one of the most innovative Indian pharmaceutical companies.
Selma Alić has joined Rhei Life as Regulatory Affairs Associate, with 7-year experience in RA and other different pharmaceutical fields. She holds a Master’s Degree in Pharmacy, from the University in Sarajevo.
Tigecycline is used to treat certain serious bacterial infections when other antibiotics may not work. It is related to a class of drugs known as tetracycline antibiotics. This project is developed with our partner manufacturing company Anfarm from Greece.
We successfully imported Liposomal Amphotericin B injection, as a non-registered medicine, to several markets in the Balkan region (Serbia, Bosnia and Herzegovina, Montenegro), with Bosnia and Herzegovina approving us the Marketing Authorization.
Our partner Amsal in Bosnia launched Memoxa 5mg (Vinpocetine) sucesfully, after more than a year of sucesful sales and marketing results with 10mg Memoxa (was launched last year)
